Previous Article | Next Article 
Infection and Immunity, January 2001, p. 386-391, Vol. 69, No. 1
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.1.386-391.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Vaccination with Calpain Induces a Th1-Biased
Protective Immune Response against Schistosoma
japonicum
Renli
Zhang,1
Ayako
Yoshida,1
Takashi
Kumagai,1
Hitoshi
Kawaguchi,1
Haruhiko
Maruyama,1
Takashi
Suzuki,1
Makoto
Itoh,2
Mohamed
El-Malky,1 and
Nobuo
Ohta1,*
Department of Medical Zoology, Nagoya City
University Medical School, Nagoya,1 and
Department of Parasitology, Aichi Medical University,
Aichi,2 Japan
Received 21 July 2000/Returned for modification 16 September
2000/Accepted 24 October 2000
 |
ABSTRACT |
A large subunit of calpain, a calcium-activated neutral proteinase,
from Schistosoma japonicum was cloned and expressed in Escherichia coli. When BALB/c mice were immunized with
purified recombinant calpain (r-calpain) emulsified in complete
Freund's adjuvant, a significant reduction in the number of recovered
worms and also in egg production per female worm was observed
(P < 0.01). Spleen cells of the immunized mice showed
enhanced production of gamma interferon (IFN-
) by activated
CD4+ T cells. Considering our observation of elevated
expression of inducible nitric oxide synthase mRNA in immunized mice,
r-calpain-induced IFN-
seemed to upregulate the production of nitric
oxide by macrophages and subsequently mediated the killing of
schistosomulae in the lung. On the other hand, spleen cells of
immunized mice showed only faint interleukin-4 production in response
to r-calpain in vitro, suggesting that immunization with r-calpain
alters the Th1-Th2 balance in murine hosts even during a Th2-promoting
S. japonicum infection. Furthermore, histopathological
study of the livers of immunized mice showed that granulomas formed
around eggs were diminished in both size and number. Egg production by female worms was clearly decreased in immunized mice, suggesting that
r-calpain also has antifecundity effects. Taken together, these results
point to S. japonicum calpain as a potential vaccine candidate for both worm killing and disease prevention, possibly through the induction of a strong Th1-dominant environment in immunized mice.
 |
INTRODUCTION |
More than 200 million people have
schistosomiasis, and almost 600 million people are exposed to the risk
of schistosomiasis (36). Chemotherapy is currently the
choice for control; however, vaccine development remains an important
long-term goal for the integrated control of schistosomiasis because of
high reinfection rates in areas where the disease is endemic. Extensive
work has been carried out to identify schistosome molecules that confer partial but significant protection in different animal models. These
include the Schistosoma mansoni 28-kDa and the
S. japonicum 26-kDa glutathione
S-transferase (GST) (5, 32), the
S. mansoni and S. japonicum 97-kDa
paramyosin (13, 25), the S. mansoni 28-kDa
triose phosphate isomerase (29), the S. mansoni 23-kDa integral membrane antigen (24), and so
forth. These vaccine candidates were selected by the World Health
Organization for a series of independent trials to test their
protective efficacy in laboratory animals (2).
Unfortunately, the stated goal of consistent induction of 40% or
better protection was not reached with any of these antigen
formulations in trials with large domestic animals (35).
Since S. japonicum infection is zoonotic, several vaccine candidates, such as the S. japonicum 26-kDa GST
or 97-kDa paramyosin, have been tested in domestic animals. Significant and promising results were obtained in some trials; however, detailed analyses are still under way. Most of the vaccine candidates were first
identified in S. mansoni, but controversy remains about whether equivalent antigens of S. japonicum could have
comparable effects because there are qualitative and/or quantitative
differences between the host immune responses to the two parasitic
infections (25).
S. japonicum is a major schistosome species in Asia,
infecting not only humans but also wild or domestic animals. Despite the availability of very successful control programs,
schistosomiasis japonica remains a serious public health problem in
China and the Philippines. Several types of economically important
livestock, such as water buffaloes and domestic pigs; act as reservoir
hosts of S. japonicum, and feces of livestock
containing S. japonicum eggs are of prime importance
for continued transmission of this parasite to humans. Control of
schistosomiasis japonica depends substantially on the successful
reduction of its prevalence in domestic livestock. Identification of an
effective vaccine is an emergent task for reducing the transmission of
S. japonicum from animals to humans in this region.
However, relatively limited numbers of antigens from S. japonicum were identified as vaccine candidates, in comparison
with S. mansoni infection (3).
Calpain from S. mansoni was shown to induce protective
immunity during murine experimental schistosomiasis mansoni
(11), and molecular cloning of calpain from S. japonicum has since started in several laboratories, including our
own (28, 38). Although calpain is believed to be an
intracellular protease, the location of this molecule seems not to be
fixed and in some cases it is moved outside of the cell membrane
(26). This suggests that calpain could have enough
immunogenicity for both humoral and cellular responses. A previous
experiment performed in our laboratory indicated that human sera from
S. japonicum-infected individuals recognized r-calpain,
and sera obtained from mice immunized with r-calpain showed enhanced
binding to cercarial antigens (38). Together with these
findings, the principal objective of our present study was to develop a
livestock vaccine that can be used to prevent Asian schistosomiasis. We
present here a study of the efficacy of r-calpain as a vaccine molecule
against a challenge infection with S. japonicum in
BALB/c mice and discuss the possible underlying mechanism of protective
immunity in immunized host animals.
 |
MATERIALS AND METHODS |
Host animals and parasites.
The life cycle of S. japonicum isolated in Yamanashi Prefecture, Japan, has been
maintained in our laboratory by using Onchomelania hupensis
nosophora with the same geographical distribution.
Six-week-old female BALB/c mice (SLC, Hamamatsu, Japan) were used
for immunization and infection experiments.
Recombinant calpain (r-calpain) from S. japonicum.
A recombinant molecule of the large subunit of calpain
from S. japonicum was prepared as described previously
(38). In brief, cDNA encoding amino acid residues 219 to
376 of S. japonicum calpain was amplified by reverse
transcription (RT)-PCR because a comparable portion was shown to be
highly immunogenic in murine schistosomiasis mansoni (17).
The product was digested by BamHI and EcoRI and then ligated into the GST fusion vector pGEX-2TK (Pharmacia, Uppsala, Sweden). This vector was transfected into Escherichia coli
DH5
cells (Pharmacia). GST fusion protein was induced in DH5
cells, and thrombin (Pharmacia) was used to isolate the r-calpain
molecule from glutathione Sepharose 4B columns (Pharmacia).
Western blot assays.
Western blotting was carried out as
described elsewhere (20). Five to 10 µg of r-calpain was
separated by sodium dodecyl sulfate-14% polyacrylamide gel
electrophoresis and transferred to a polyvinylidene difluoride membrane
(Millipore Corporation, Bedford, Mass.). Mouse anti-r-calpain serum was
used as the primary antibody, and the secondary antibody used was goat
anti-mouse IgG labeled with peroxidase (Kirkegaard & Perry
Laboratories, Gaithersburg, Md.) at a final dilution of 1:3,000. The
substrate used was 4-chloro-1-naphthol.
Immunization schedule.
Mice were divided into two groups in
the first experiment and three groups in the second experiment. An
immune-challenge group of 18 mice was injected subcutaneously (s.c)
with 25 µg of r-calpain dissolved in phosphate-buffered saline (PBS)
with complete Freund's adjuvant (Gibco, Grand Island, N.Y.). The mice
were boosted s.c. with 25 µg of r-calpain dissolved in PBS with
incomplete Freund's adjuvant (Gibco) 2 weeks later and were further
boosted intravenously 2 weeks later with 25 µg of r-calpain dissolved
in PBS. An adjuvant-treated control group comprising 18 mice was
subjected to the same immunization schedule as the immune-challenge
group, but PBS replaced r-calpain. Ten mice with no treatment were used
as a challenge control group. In our second experiment, we prepared an
additional group of 12 mice immunized s.c. with 100 irradiated
cercariae (48 × 103 rads), and this group was boosted
twice every 2 weeks. Two weeks after the final boosting, all groups
were infected percutaneously with 30 cercariae of S. japonicum by the cover glass method.
RT-PCR for iNos, eNos, and Nos mRNAs.
Four days after
the challenge infection, whole lungs of four mice were removed from
r-calpain-immunized or adjuvant-treated control group mice and
immediately frozen in liquid nitrogen in order to detect expression of
inducible, neuronal, and endothelial nitric oxide synthase (iNos, nNos,
and eNos, respectively) mRNAs. Total RNA from the lungs of the mice
was isolated using PUREscript reagents (Gibco) in accordance with the
manufacturer's instructions. RNA samples were stored at
80°C until
use. First-strand DNA synthesis was carried out with 1 µg of RNA in
20-µl of reaction solution using an RNA-PCR kit (Perkin-Elmer,
Branchburg, Calif.). The primer sequence and PCR conditions used for
amplification of nNos and eNos were reported previously
(10).
-Actin was used as a control. The iNos primers
used were as follows: sense 5' ctggaggagctcctgcctcatg 3';
antisense; 5' gcagcatcccctctgatggtg 3'. These
primers amplify a 449-bp fragment of iNos mRNA. The PCR solution
contained 2 µl of cDNA, 50 mM KCl (pH 8.4), 20 mM Tris-HCl, 1.5 mM
MgCl2, 200 mM deoxynucleoside triphosphates, 2 U of
Taq gold DNA polymerase (all from Perkin-Elmer); and 1.2 mM
primers in a 50-µl volume. The PCR mixture was subjected to 35 cycles, and the annealing temperature was 60°C. PCR products were
evaluated on a 2% agarose gel with ethidium bromide by using a
densitometry analyzer.
Worm recovery and tissue sampling.
Six weeks after a
challenge infection, all vaccinated and control mice were sacrificed
and perfusion was undertaken to recover the worms. The worm reduction
rate, percent protection, was calculated according to the following
formula: (1
mean number of worms in immunized mice/mean number
of worms in adjuvant or challenge control mice) × 100. Before the
perfusion, spleens from each group were removed to test cytokine
production in vitro. At the time of perfusion, the livers and
intestines of mice from all groups were weighed. The livers and
intestines were digested with 4% KOH overnight, and the number of eggs
was determined by microscopic examination. We determined egg counts for
each gram of liver or intestine, and the mean number of eggs per female
adult schistosome was also calculated.
Cytokine production analysis.
Two weeks after the final
boosting, spleen cells from each group of mice were cultured in RPMI
1640 medium supplemented with 10% fetal calf serum in the presence of
concanavalin A (ConA, Sigma) or r-calpain at 10 µg/ml at 37°C with
5% CO2 (prechallenge). The same testing was done at 6 weeks after the challenge infection (postchallenge). For testing of
interleukin-4 (IL-4) and gamma interferon (IFN-
) production,
107 cells were cultured for 48 h in 2 ml of medium in
24-well plates (Nunc). The cell-free culture supernatants were used for
measurement of the two cytokines by quantitative sandwich enzyme
immunoassay kits (Genzyme, Minneapolis, Minn.).
Histopathological examination.
After portal perfusion, the
liver was dissected and immediately fixed in 10% buffered formalin for
morphometric analysis. Liver sections were embedded in paraffin and
stained with hematoxylin and eosin for microscopic examination.
Hematoxylin-eosin-stained sections of the liver were then searched for
granulomas. We assessed the sizes of nonconfluent granulomas formed
around a single egg containing a mature miracidium by using a video
micrometer (VM-30; Olympus, Tokyo, Japan) in accordance with the
manufacturer's instructions. We also evaluated the mean percentage of
granulomatous areas in 1-mm2 liver sections.
Statistical analysis.
For statistical evaluation of data, we
used a two-sided Student t test.
 |
RESULTS |
Preparation of r-calpain and production of anti-r-calpain antibody
in mice.
We prepared an r-calpain molecule, and the purified
protein was confirmed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (Fig. 1). Mice immunized
with r-calpain produced a high level of IgG antibodies specific to the
immunizing antigen. Six weeks after the immunization and prior to a
challenge infection, optical density values (mean ± standard
deviation) of anti-r-calpain antibody in the immunized mice and
adjuvant controls were 1.037 ± 0.006 and 0.163 ± 0.009, respectively. The mean optical density value anti-r-calpain antibody in
immunized mice was significantly higher than that in adjuvant controls
(P < 0.01). Immunoblotting analysis showed murine
anti-r-calpain serum binding specifically to r-calpain (Fig. 1),
indicating that the protocol for immunization of mice with r-calpain
functioned properly in our present study.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 1.
Immunoblot analysis of r-calpain of S. japonicum. R-calpain was fractionated and transferred to a
polyvinylidene difluoride membrane (lane 3) and then subjected to
immunostaining (lanes 1 and 2). Lane 3 was stained with Coomassie
brilliant blue. IgG antibody specific to r-calpain is detected on
immunoblotting membrane using sera of immunized mice (lane 2).
Adjuvant-treated control mouse serum (negative control) is shown in
lane 1.
|
|
Protective immunity induced by immunization with r-calpain.
Figure 2 shows the number of worms
recovered mice with or without immunization. In the repeated
experiments, the worm reduction rate in immunized mice was 36.7% for
experiment 1 and 41.2% for experiment 2 in comparisons with that in
adjuvant-treated controls (P < 0.05). In experiment 2, 48.3% protection was provided by immunization with
radiation-attenuated cercariae compared with adjuvant-treated controls.
There was no significant difference in worm recovery between
immunization with r-calpain and immunization with attenuated cercariae.
We observed r-calpain-mediated effects on egg counts in the liver and
intestine and total lymphocyte counts in the spleen (Table
1). There was a substantial reduction in
the total number of eggs present in the liver and intestine in mice
immunized with r-calpain or with irradiated cercariae in comparison
with adjuvant-treated controls (P < 0.01).
Furthermore, mice immunized with r-calpain showed a significant
reduction in egg laying per female worm while there was no difference
in this parameter in the case of immunization with radiation-attenuated cercariae (P < 0.01). As for the mean lymphocyte
number in the spleen, mice immunized with r-calpain showed a decreased
lymphocyte count compared with that in adjuvant-treated controls. There
was no difference in liver and intestine weights among any of the groups (data not shown).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 2.
Adult-worm burden were assessed in two different
experiments (Exp. 1 and Exp. 2). Columns: open; challenge control mice;
hatched, adjuvant-treated control mice; solid,
calpain-immunized mice; dotted, mice immunized with irradiated
cercariae. A significant worm burden difference was found between
calpain-immunized mice and adjuvant-treated controls (36.7% reduction
in experiment 1 and 41.2% reduction in experiment 2). *,
P < 0.05; **, P < 0.01. SD,
standard deviation.
|
|
mRNA expression of each NOS isoform.
We compared
expression of mRNA for three NOS isoforms in lungs removed from
either r-calpain-immunized mice or adjuvant-treated control mice (Fig.
3). We observed significant increases in
iNos mRNA expression in r-calpain-immunized mice compared with that in adjuvant-treated controls (P < 0.02). On the other
hand, there was no difference in eNos and nNos mRNA expression
between the two groups, although the latter showed a weak elevation.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 3.
RT-PCR detection of mRNA for NOS isoforms in
r-calpain-immunized and adjuvant-treated control mice. (A) Primers
detection of unique sequences of each isoform and produced fragments
(254, 404, and 449 bp for eNos, nNos, and iNos transcripts,
respectively). A 348-bp fragment of actin was used as a control. Lanes:
1 to 4, r-calpain-immunized mice; 5 to 8, adjuvant-treated controls.
(B) Significant difference in iNos mRNA expression between
r-calpain-immunized and adjuvant-treated control mice. Bars: solid,
r-calpain-immunized group; open, adjuvant-treated control. *,
P < 0.02.
|
|
Cytokine production.
We measured the cytokine production of
spleen cells in response to ConA or r-calpain on day 42 after a
challenge infection (Fig. 4). Although
schistosome infection is generally thought to be a strong Th2 inducer,
spleen cells of control mice, both adjuvant-alone and infection control
mice, did not show a typical type 2 pattern in r-calpain-driven
cytokine production. Even in this case, we observed a significant
reduction of IL-4 production and enhanced production of IFN-
in
response to r-calpain in mice immunized with r-calpain. A high level of
r-calpain-driven IFN-
production was also detected in mice treated
with radiation-attenuated cercariae. IFN-
production by spleen cells
from mice immunized with r-calpain and with radiation-attenuated
cercariae was significantly higher than in control mice (P < 0.01). However, spleen cells stimulated by ConA showed no
difference in IFN-
production among all four of the groups tested.
The kinetics of r-calpain-driven IL-4 and IFN-
production was
studied: mice immunized with r-calpain showed strong IFN-
production
after vaccination and prior to challenge infection, whereas the IL-4
response was suppressed only after a challenge infection (Fig. 5C and
D). Upregulation of the Th1 response
during challenge infection was, thus, an apparent finding in mice
immunized with r-calpain.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 4.
IFN- and IL-4 production by murine spleen cells (six
in each group) stimulated with a mitogen or calpain in vitro. Cytokine
production was evaluated in culture supernatants. Data correspond to
the mean values from duplicate analyses. Bars: open, calpain-immunized
mice; closed, adjuvant-treated controls; hatched, infection controls;
dotted, mice immunized with irradiated cercariae. *, P < 0.05; **, P < 0.01.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
Kinetics of cytokine production in murine spleen cells
stimulated by ConA (A and B) or r-calpain (C and D) in
r-calpain-immunized and adjuvant-treated control mice. Cytokines were
detected at three different time points. A and C refer to IFN-
production, and B and D refer to IL-4 production. Cytokine profiles of
calpain-immunized mice are shown as circles, and those of
adjuvant-treated control mice are shown as open squares. A marked
increase in calpain-driven IFN- production and a decrease in IL-4
production were observed for the calpain-immunized group compared with
the adjuvant-treated control group. *, P < 0.05;
**, P < 0.01.
|
|
Histopathology of egg granulomas.
Egg granulomas formed after
a challenge infection were quite a bit smaller in size and lower in
number in the livers of r-calpain-immunized mice compared with those of
the adjuvant-treated control group. The mean area of nonconfluent
granulomas in the liver was significantly smaller in
r-calpain-immunized mice (578.13 ± 257 µm2) than that in
adjuvant controls (1,522.12 ± 516 µm2)
(P < 0.001) (Fig. 6A).
Furthermore, there was a more widespread granulomatous lesion in
adjuvant-treated control mice than in the r-calpain-immunized group.
According to our observation of liver sections, the mean percentage of
the area occupied by granulomas was significantly different in
r-calpain-immunized mice (11.6%) and adjuvant-treated control mice
(22.1%) (P < 0.001) (Fig. 6B).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 6.
Comparison of granuloma size (A) and density (B) in the
livers of adjuvant-treated control and immunized mice. Bars: solid,
calpain-immunized group; hatched, adjuvant-treated control mice. The
mean areas of single-egg granulomas and the mean areas occupied by
granulomas in liver sections were compared between groups.
|
|
 |
DISCUSSION |
In the present study, we showed the efficacy of calpain as a
vaccine against murine schistosomiasis japonica. Calpains are ubiquitously expressed in a wide variety of eukaryotic cell types in
vivo, and it is likely that calpain modifies various regulatory and
structural proteins, including the cytoskeleton, as well as inducing
programmed cell death (8, 27). The biological roles of
calpain in schistosome parasites are not fully understood. Calpain was
shown to be an immunogenic protein that exists on or near the surface
of the schistosome and is important in parasite membrane shedding and
renewal (1, 19, 31). In recent vaccine development using
calpain from schistosomes, Hota-Michell and coworkers reported that
r-calpain afforded 39% protection against a challenge infection with
S. mansoni (11), and DNA vaccine containing cDNA encoding S. mansoni calpain provided
60% protection (12). Our results also showed that
S. japonicum r-calpain afforded more than 40%
protection against a challenge infection of BALB/c mice with
S. japonicum. The present study of S. japonicum showed that calpain induced not only a reduction in worm
burden but also a reduction in egg laying per female worm in immunized
mice. To our knowledge, this is the first report showing antifecundity effects of calpain on S. japonicum infecting mice.
Calpain from S. japonicum seems to be a good candidate
for a disease-controlling vaccine, an important step in overcoming
S. japonicum infection, which causes more-severe
hepatic damage through egg deposition in host animals than does an
S. mansoni infection (23).
The mechanism by which r-calpain-immunized mice can induce reductions
in both the worm burden and the egg production of female worms is still
unclear. It has been previously reported that a helper T-cell clone
recognizing the large subunit of S. mansoni calpain
carried protective effects in C57BL/6 mice against cercarial challenge
(11). The helper T-cell clone produced large amounts of
IFN-
in response to a truncated calpain-GST fusion protein, indicating that the protective T cells were of the Th1 phenotype (17). There is a consensus that Th1 cells are important in
protective immunity against schistosome infection of mice. Previous
publications have shown that mice immunized with radiation-attenuated
cercariae eliminated 60 to 80% of the worms (14). Several
lines of evidence suggest that responses involving IFN-
-activated
effector cells are the major mechanism of protection mediated by
attenuated cercariac (15, 21, 33). In the present study,
immunization with r-calpain again up-regulated IFN-
production
during a challenge infection of mice with S. japonicum.
The precise mechanisms of IFN-
-mediated parasite elimination remain
to be uncovered. James and coworkers reported killing mechanisms
against lung stage schistosomulae by a NO-mediated killing mechanism
(9, 16). This is not inconsistent with a recent report on
a study in which iNOS mRNA was up-regulated at the time of parasite
elimination (37), although other groups have disagreed
with these findings (33). Other groups have shown that
IFN-
up-regulates iNos expression followed by NO production (18). Our results also suggest NO-mediated killing of lung
stage schistosomulae, because there was a significant increase in the expression of iNOS mRNA in the lungs of r-calpain-immunized mice 4 days after a challenge infection. This was the time point when migrating larvae reached the lungs of host animals. Considering recent
reports along with our current findings, NO seems to be involved in the
protective mechanism mediated by immunization with r-calpain in
schistosomiasis japonica. Further analysis is, however, still needed,
as others have reported iNOS knockout mice with vaccine-mediated
protection against S. mansoni (7).
Schistosomiasis caused a host response to trapped parasite eggs in the
tissue resulting in the formation of granulomatous lesions in the liver
and intestine. A reduction in egg number could be tightly related to
lowered pathological severity in the immunized mice. Brunet et al.
reported that mice treated with aminoguanidine, a selective inhibitor
of iNos expression, developed severe morbidity and increased hepatic
damage (4). In the present study, hepatic damage caused by
egg deposition was reduced in the r-calpain-immunized group. Although
we did not measure the expression of iNos mRNA in the liver,
r-calpain could protect the immunized hosts from developing severe
hepatic damage by expression of iNos mRNA through a systemic shift
to a Th1-dominant situation. The number of deposited eggs in
r-calpain-immunized mice was markedly reduced not only by a reduction
in the number of adult worms but also by lowered fecundity of female
worms. Attenuated cercariae did not induce such an antifecundity effect
even though both immunizations stimulated strong Th1 responses. This
might suggest that the antifecundity effect is mediated by a factor
different from the function of IFN-
. It is interesting to analyze
whether calpain is critically involved in egg production by female
schistosomes, as this might point to calpain as a possible target
molecule for developing a prophylactic reagent(s).
Because an attenuated cercarial vaccine would not be practical for use
in humans and livestock, investigators have attempted to use protective
mechanisms defined in the model to develop a nonliving vaccine. In our
experiments, we compared protective immune effects between
radiation-attenuated cercariae and r-calpain. Although
radiation-attenuated cercariae could induce greater protection, as was
also observed by Chen et al. (6), it did not reduce egg
production per female worm. Furthermore, it was interesting that
r-calpain promoted only high IFN-
production while
radiation-attenuated cercariae induced high production of both IL-4 and
IFN-
after challenge infection. This suggests that there are somehow
fundamental differences between the immune mechanisms of the protective
effects of these two vaccine models.
In conclusion, our present study showed that r-calpain of S. japonicum could induce more than 40% protection against a
challenge infection, reduce egg production by female worms, and also
reduce hepatic damage in BALB/c mice. These results are highly
suggestive for a future trial of calpain of S. japonicum as a vaccine candidate for livestock in the hope of
controlling human schistosomiasis in Asian countries.
 |
ACKNOWLEDGMENTS |
T. Amano, Department of Parasitology, Yokohama City University
Medical School, kindly provided snails used in the present study. We
thank T. Kadosaka and X. G. Qiu, Aichi Medical University, for
scientific and technical assistance in egg granuloma histopathological analysis.
This study was supported in part by a Grant-in-Aid for Scientific
Research from the Ministry of Education, Culture and Sports, Japan
(12576009); a grant for Emerging and Re-emerging Infectious Diseases
from the Ministry of Health and Welfare (12101801); and a grant from
the Japan-US Cooperative Medical Science Program (1999-2000).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medical Zoology, Nagoya City University Medical School, 1 Azakawasumi, Mizuhocho, Mizuhoku, Nagoya 467-8601, Japan. Phone: 81-52-853-8184. Fax: 81-52-842-0149. E-mail:
nohta{at}med.nagoya-cu.ac.jp.
Editor:
W. A. Petri Jr.
 |
REFERENCES |
| 1.
|
Andresen, K.,
T. D. Tom, and M. Strand.
1991.
Characterization of cDNA clones encoding a novel calcium-activated neutral proteinase from Schistosoma mansoni.
J. Biol. Chem.
266:15085-15090[Abstract/Free Full Text].
|
| 2.
|
Bergquist, R.
1995.
Controlling schistosomiasis by vaccination: a realistic option?
Parasitol. Today
11:191-194[CrossRef].
|
| 3.
|
Bergquist, R., and D. G. Colley.
1998.
Schistosome vaccine: research to development. The search for a schistosomiasis vaccine.
Parasitol. Today
14:97-118.
|
| 4.
|
Brunet, L. R.,
M. Beall,
D. W. Dunne, and E. J. Pearce.
1999.
Nitric oxide and the Th2 response combine to prevent severe hepatic damage during Schistosoma mansoni infection.
J. Immunol.
163:4976-4984[Abstract/Free Full Text].
|
| 5.
|
Capron, A.,
J. P. Dessaint,
M. Capron, and R. J. Pierce.
1992.
Vaccine strategies against schistosomiasis.
Immunobiology
184:282-292[Medline].
|
| 6.
|
Chen, H.,
T. Nara,
X. Zheng,
M. Satoh,
G. Wu,
W. Jiang,
F. Yi,
S. Kojima,
K. S. Zhang, and K. Hirayama.
2000.
Vaccination of domestic pig with recombinant paramyosin against Schistosoma japonicum in China.
Vaccine
18:2142-2146[CrossRef][Medline].
|
| 7.
|
Coulson, P. S.,
L. E. Smythies,
C. Betts,
N. A. Mabbott,
J. M. Sternberg,
X-G. Wei,
F. Y. Liew, and R. A. Wilson.
1998.
Nitric oxide produced in the lungs of mice immunized with the radiation-attenuated schistosome vaccine is not the major agent causing challenge parasite elimination.
Immunology
93:55-63[CrossRef][Medline].
|
| 8.
|
Croall, D. E., and G. N. Demartino.
1991.
Calcium-activated neutral protease (calpain) system: structure, function, and regulation.
Physiol. Rev.
71:813-847[Free Full Text].
|
| 9.
|
Green, S. J., and C. A. Nacy.
1993.
Antimicrobial and immunopathologic effect of cytokine-induced nitric oxide synthesis.
Curr. Opin. Infect. Dis.
6:384-391.
|
| 10.
|
Hara, H.,
C. Ayata,
P. L. Huang,
C. Waeber,
G. Ayata,
M. Fujii, and M. A. Mokowitz.
1997.
[3H]L-NG-nitroarginine binding after transient focal ischemia and NMDA-induced excitotoxicity in type I and type III nitric oxide synthase null mice.
J. Cereb. Blood Flow Metab.
17:515-526[CrossRef][Medline].
|
| 11.
|
Hota-Michell, S.,
A. A. Siddiqui,
G. A. Dekabab,
J. Smith,
C. Tognon, and R. B. Podesta.
1997.
Protection against Schistosoma mansoni infection with recombinant baculovirus-expressed subunit of calpain.
Vaccine
15:1631-1640[CrossRef][Medline].
|
| 12.
|
Hota-Michell, S.,
W. Michael,
R. B. Clarke,
R. B. Podesta, and G. A. Dekaban.
1999.
Recombinant vaccine and gene gun vectors expressing the large subunit immunization-challenge model.
Vaccine
17:1338-1354[CrossRef][Medline].
|
| 13.
|
James, S. L.
1987.
Schistosoma spp.: progress towards a defined vaccine.
Exp. Parasitol.
63:247-252[CrossRef][Medline].
|
| 14.
|
James, S. L.,
M. Labine, and A. Sher.
1981.
Mechanism of protection immunity against Schistosoma mansoni infection in mice vaccinated with irradiated cercariae. Analysis of antibody and T-lymphocyte responses in mouse strains developing different levels of immunity.
Cell. Immunol.
65:75-83[CrossRef][Medline].
|
| 15.
|
James, S. L.,
P. C. Natovitz,
W. L. Farrar, and E. J. Leonard.
1984.
Macrophages as effector cells of protective immunity in murine schistosomiasis: macrophage activation in mice vaccinated with radiation-attenuated cercariae.
Infect. Immun.
44:569-575[Abstract/Free Full Text].
|
| 16.
|
James, S. L., and J. Glaven.
1989.
Macrophage cytotoxicity against schistosomula of Schistosoma mansoni involves arginine-dependent protection of reactive nitrogen intermediates.
J. Immunol.
143:4208-4212[Abstract].
|
| 17.
|
Jankovic, D.,
L. Aslund,
I. P. Oswald,
P. Caspar,
C. Pearce,
J. E. Coligan,
M. Strand,
A. Sher, and S. L. James.
1996.
Calpain is a target antigen of a Th1 clone that transfers protective immunity against Schistosoma mansoni.
J. Immunol.
157:806-814[Abstract].
|
| 18.
|
Kamijo, R.,
D. Shapiro,
J. Li,
S. Huang,
M. Aguet, and J. Vileck.
1993.
Generation of nitric oxide and induction of major histo-compatibility class II antigen in macrophages from mice lacking the interferon- receptor.
Proc. Natl. Acad. Sci. USA
90:6626-6630[Abstract/Free Full Text].
|
| 19.
|
Karcz, S. R.,
R. B. Podesta,
A. A. Siddiqui,
G. A. Dekaban,
G. H. Strejan, and M. W. Clarke.
1991.
Molecular cloning and sequence analysis of a calcium activated neutral protease (calpain) from Schistosoma mansoni.
Mol. Biochem. Parasitol.
49:333-336[CrossRef][Medline].
|
| 20.
|
Kawaguchi, H., and T. Takayanagi.
1998.
Identification of a new fluke allergen identified by monoclonal IgE antibodies for Paragonimus miyazaki.
J. Parasitol.
84:307-310[CrossRef][Medline].
|
| 21.
|
Kelly, E., and D. G. Colly.
1988.
In vitro effect of monoclonal anti-L3T4 antibody on immune responsiveness of mice infected with Schistosoma mansoni: reduction of irradiated cercariae-induced resistance.
J. Immunol.
140:2737-2745[Abstract].
|
| 22.
|
Kojima, S.,
M. Niimura, and T. Kanazawa.
1987.
Production and properties of a mouse monoclonal IgE antibody to Schistisoma japonicum.
J. Immunol.
139:2044-2049[Abstract].
|
| 23.
|
Meleney, H. E.,
J. H. Sabdground,
D. V. Moore,
H. Most, and B. H. Carney.
1953.
The histopathology of experimental schistosomiasis. II. Bisexual infections with S. mansoni, S. japonicum, and S. haematobium.
Am. J. Trop. Med. Hyg.
2:883-913.
|
| 24.
|
Reynold, S. R.,
B. S. Charles, and A. H. Donald.
1992.
T and B cell epitope mapping of Sm23, an integral membrane protein of Schistosoma mansoni.
J. Immunol.
149:3995-4001[Abstract].
|
| 25.
|
Ross, A. G. P.,
A. C. Sleigh,
Y. S. Li,
G. M. Williams,
G. D. L. Aligui, and D. P. McManus.
2000.
Is there immunity to Schistosoma japonicum?
Parasitol. Today
16:159-164[CrossRef][Medline].
|
| 26.
|
Saido, T. C.,
H. Suzuki,
H. Yamazaki,
K. Tanoue, and K. Suzuki.
1993.
In situ capture of µ-calpain activation in platelets.
J. Biol. Chem.
268:7422-7426[Abstract/Free Full Text].
|
| 27.
|
Saido, T. C.,
H. Sorimachi, and K. Suzuki.
1994.
Calpain: new perspectives in molecular diversity and physiological-pathological involvement.
FASEB J.
8:814-822[Abstract].
|
| 28.
|
Scott, J. C., and D. P. McManus.
2000.
Characterization and expression of cDNA encoding the 80-kDa large subunit of Schistosoma japonicum calpain.
Parasitol. Int.
48:205-214[CrossRef][Medline].
|
| 29.
|
Shoemaker, C.,
A. Gross,
A. Gebremichael, and D. A. Harn.
1992.
cDNA cloning and functional expression of the Schistosoma mansoni protective antigen triose phosphate isomerase.
Proc. Natl. Acad. Sci. USA
89:1842-1846[Abstract/Free Full Text].
|
| 30.
|
Shuxian, L.,
S. Guangchen,
X. Yuxian,
W. Yang, and D. P. Mcmanus.
1995.
Immunization of mice with recombinant Sjc 26GST induces a pronounced anti-fecundity effect after experimental infection with Chinese Schistosoma japonicum.
Vaccine
13:603-607[CrossRef][Medline].
|
| 31.
|
Siddiqui, A. A.,
Y. Zhou,
R. B. Podesta,
S. R. Karcz,
C. E. Tognon,
G. H. Strejan, and G. A. Dekaban.
1993.
Characterization of Ca2+-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni.
Biochiem. Biophys. Acta
1181:37-44.
|
| 32.
|
Smith, D. B.,
M. R. Rubia,
R. J. Simpson,
K. Davern,
W. U. Tiu,
P. G. Board, and G. F. Mitchell.
1988.
Expression of an enzymatically active parasite molecule in Escherichia coli: Schistosoma japonicum glutathione-S-transferase.
Mol. Biochem. Parasitol.
27:249-256[CrossRef][Medline].
|
| 33.
|
Smythies, L. E.,
P. S. Coulson, and R. A. Wilson.
1992.
Monoclonal antibody to IFN- modifies pulmonary inflammatory responses and abrogates immunity to Schistosoma japonicum in mice vaccinated with attenuated cercariae.
J. Immunol.
149:3654-3658[Abstract].
|
| 34.
|
Wilson, R. A., and P. S. Coulson.
1998.
Why don't we have a schistosomiasis vaccine?
Parasitol. Today
14:97-99.
|
| 35.
|
World Health Organization.
1996.
Tropical diseases research, no. 50.
World Health Organization, Geneva, Switzerland.
|
| 36.
|
World Health Organization.
1988.
The world health report 1997.
World Health Organization, Geneva, Switzerland.
|
| 37.
|
Wynn, T. A.,
I. P. Oswala, and I. A. Eltoum.
1994.
Elevated expression of Th1 cytokines and nitric oxide synthase in the lungs of vaccinated mice after challenge infection with Schistosoma mansoni.
J. Immunol.
153:5200-5209[Abstract].
|
| 38.
|
Zhang, R. L.,
T. Suzuki,
S. Takahashi,
A. Yoshida,
H. Kawaguchi,
H. Maruyama,
Y. Yabu,
J. Fu,
T. Shirai, and N. Ohta.
2000.
Cloning and molecular characterization of calpain, a calcium-activated neutral proteinase, from different strains of Schistosoma japonicum.
Parasitol. Int.
48:233-242[CrossRef].
|
Infection and Immunity, January 2001, p. 386-391, Vol. 69, No. 1
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.1.386-391.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kong, W.-p., Xu, L., Stadler, K., Ulmer, J. B., Abrignani, S., Rappuoli, R., Nabel, G. J.
(2005). Modulation of the Immune Response to the Severe Acute Respiratory Syndrome Spike Glycoprotein by Gene-Based and Inactivated Virus Immunization. J. Virol.
79: 13915-13923
[Abstract]
[Full Text]
-
Siddiqui, A. A., Phillips, T., Charest, H., Podesta, R. B., Quinlin, M. L., Pinkston, J. R., Lloyd, J. D., Paz, M., Villalovos, R. M., Pompa, J.
(2003). Induction of Protective Immunity against Schistosoma mansoni via DNA Priming and Boosting with the Large Subunit of Calpain (Sm-p80): Adjuvant Effects of Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-4. Infect. Immun.
71: 3844-3851
[Abstract]
[Full Text]